Previous 10 | Next 10 |
CorMedix (NASDAQ:CRMD) announces changes to its executive leadership team with Khoso Baluch retiring from his role as CEO, effective October 4, 2021, and has also resigned from the Company’s Board of Directors. John Armstrong, EVP for Technical Operations, is retiring from CorMedi...
BERKELEY HEIGHTS, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced changes to its executiv...
Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021 PR Newswire WASHINGTON , Sept. 30, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug resistant infections and s...
NEW YORK, NY / ACCESSWIRE / September 13, 2021 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz ...
CorMedix (NASDAQ: CRMD) stock was getting crushed on Tuesday, with shares down 23.7% as of 11 a.m. EDT. The decline came after the company announced that it "has encountered delays at its third-party contract manufacturer." These delays will push back CorMedix's refiling for U.S. Fo...
Gainers: ZIOPHARM Oncology (NASDAQ:ZIOP) +39%, RenovoRx (NASDAQ:RNXT) +17%, Sigilon Therapeutics (NASDAQ:SGTX) +17%, Acumen Pharmaceuticals (NASDAQ:ABOS) +15%, NeuroOne Medical Technologies (NASDAQ:NMTC) +7%. Losers: CorMedix (NASDAQ:CRMD) -25...
BERKELEY HEIGHTS, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today provided an update with respect ...
Image source: The Motley Fool. CorMedix Inc Common Stock (NASDAQ: CRMD) Q2 2021 Earnings Call Aug 12, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: CorMedix Inc Common Stock (CRMD) Q2 2021 Earnings Call Transcript...
CorMedix Inc. (CRMD) Q2 2021 Earnings Conference Call August 12, 2021, 04:30 PM ET Company Participants Dan Ferry - LifeSci Advisors, IR Khoso Baluch - CEO Phoebe Mounts - EVP and General Counsel Matt David - EVP and CFO Conference Call Participants Jason Butler - JMP Securities Joon Lee - Tr...
BERKELEY HEIGHTS, N.J., Aug. 12, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced financial results for t...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 12:00:00 ET July 11, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at recent news and developments in the blood infections treatment market, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:C...
BERKELEY HEIGHTS, N.J., July 03, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has commenced commercialization of DefenCath ® (tauroli...
BERKELEY HEIGHTS, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that the U.S. Food and Drug Administration (FDA) has...